Literature DB >> 16144974

Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.

Sandra D Comer1, Maria A Sullivan, Ellen A Walker.   

Abstract

Although buprenorphine is used worldwide as a safe and effective maintenance medication for opioid dependence, some countries have reported a growing incidence of abuse of this medication. Buprenorphine is considered to have lower abuse potential because of its partial agonist profile, but no studies have directly compared the reinforcing effects of buprenorphine with those of full mu opioid agonists in humans. The present double-blind, placebo-controlled inpatient study compared the reinforcing and subjective effects of intravenously administered buprenorphine (0.5, 2, and 8 mg) and methadone (5, 10, and 20 mg). Participants (n = 6) were detoxified from heroin during the first 1 to 2 weeks after admission. During subsequent weeks, participants received a sample drug dose and $20 on Monday, and they could self-administer either the sampled dose or $20 during one choice session per day on Thursday and Friday. Participants responded under a modified progressive ratio schedule during each choice session. All active doses maintained higher progressive ratio break points (largest completed ratio) than placebo. There were no significant differences in break point values between buprenorphine and methadone or among the different doses of drug. However, several subjective ratings, including "good drug effect", "high", and "liking" dose-dependently increased after administration of buprenorphine and methadone. The peak ratings for these effects did not significantly differ for the two drugs. These results demonstrate that under these experimental conditions, buprenorphine and methadone were equally effective in producing reinforcing and subjective effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144974      PMCID: PMC4079467          DOI: 10.1124/jpet.105.090423

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids.

Authors:  A C Barrett; C D Cook; J M Terner; R M Craft; M J Picker
Journal:  Psychopharmacology (Berl)       Date:  2001-11       Impact factor: 4.530

2.  Choice between money and intranasal heroin in morphine-maintained humans.

Authors:  S D Comer; E D Collins; M W Fischman
Journal:  Behav Pharmacol       Date:  1997-12       Impact factor: 2.293

3.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

4.  Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Authors:  S L Walsh; K L Preston; G E Bigelow; M L Stitzer
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

5.  Bioavailabilities of rectal and oral methadone in healthy subjects.

Authors:  Ola Dale; Pamela Sheffels; Evan D Kharasch
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

6.  Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.

Authors:  E C Strain; K L Preston; I A Liebson; G E Bigelow
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

7.  Progressive ratio performance maintained by buprenorphine, heroin and methadone in Macaque monkeys.

Authors:  N K Mello; S E Lukas; M P Bree; J H Mendelson
Journal:  Drug Alcohol Depend       Date:  1988-05       Impact factor: 4.492

8.  Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.

Authors:  R C Pitts; R M Allen; E A Walker; L A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  1998-06       Impact factor: 4.030

9.  In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.

Authors:  J E Dum; A Herz
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

10.  A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics.

Authors:  T P Miller; J L Taylor; J R Tinklenberg
Journal:  Neuropsychobiology       Date:  1988       Impact factor: 2.328

View more
  22 in total

Review 1.  A review of human drug self-administration procedures.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

Review 2.  The role of human drug self-administration procedures in the development of medications.

Authors:  S D Comer; J B Ashworth; R W Foltin; C E Johanson; J P Zacny; S L Walsh
Journal:  Drug Alcohol Depend       Date:  2008-04-24       Impact factor: 4.492

3.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

Review 4.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

5.  Human sex differences in d-amphetamine self-administration.

Authors:  Andrea R Vansickel; William W Stoops; Craig R Rush
Journal:  Addiction       Date:  2010-02-09       Impact factor: 6.526

6.  The drug effects questionnaire: psychometric support across three drug types.

Authors:  Meghan E Morean; Harriet de Wit; Andrea C King; Mehmet Sofuoglu; Sandra Y Rueger; Stephanie S O'Malley
Journal:  Psychopharmacology (Berl)       Date:  2012-12-28       Impact factor: 4.530

7.  The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.

Authors:  Jermaine D Jones; Maria A Sullivan; Jeanne Manubay; Suzanne K Vosburg; Sandra D Comer
Journal:  Neuropsychopharmacology       Date:  2010-10-27       Impact factor: 7.853

8.  The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

Authors:  Jermaine D Jones; Gabriela Madera; Sandra D Comer
Journal:  Pharmacol Biochem Behav       Date:  2014-05-02       Impact factor: 3.533

9.  Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.

Authors:  Jermaine D Jones; Taylor Speer; Sandra D Comer; Stephen Ross; John Rotrosen; Malcolm S Reid
Journal:  Am J Drug Alcohol Abuse       Date:  2013-03       Impact factor: 3.829

Review 10.  Clinical models of decision making in addiction.

Authors:  Mikhail N Koffarnus; Brent A Kaplan
Journal:  Pharmacol Biochem Behav       Date:  2017-08-26       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.